Quick Read – Humana (HUM) received an aggressive upgrade from Deutsche Bank to Buy with a $441 price target (nearly double the previous $235) and a price target raise from Mizuho to $335, driven by expectations that Medicare star ratings will recover and drive bonus payments and…
an positioning in 2026. – Deutsche Bank views 2026 as an earnings bottom and rebasing year for Humana, with the managed care market stabilizing and stars results in October serving as the key catalyst for the recovery narrative. – The analyst who called NVIDIA in 2010 just named his top 10 stocks and Humana wasn’t one of them. Get them here FREE
Deutsche Bank just delivered one of the most aggressive analyst upgrades of 2026 on Humana (NYSE:HUM), lifting the managed care giant to Buy from Hold while nearly doubling its price target to $441 from $235. The move signals that one of Wall Street’s more cautious voices now sees a fundamental reset in the Humana franchise. Adding to the bullish chorus, Mizuho raised its Humana price target to $335 from $290 and kept an Outperform rating, citing a reduced likelihood of negative medical loss ratio shifts through 2026.
For prudent investors weighing a healthcare rebound trade, the upgrade reframes Humana stock as a recovery story rather than a falling knife. The Analyst’s Case Deutsche Bank’s thesis rests on a stabilizing managed care market and an expectation that Humana’s Medicare star ratings will recover. Star ratings drive bonus payments, premium positioning, and enrollee plan selection during Annual Election Period shopping.